Tom Castellano: Yes. Sure, Tejas. So thanks for the question. Yes. So your numbers are spot on in terms of FX, we did talk about FX impact of 3 to 4 points on revenue in EBITDA. We do see a little bit more of an impact to the to the bottom line from FX than we do it in the top line just given the geographic I would say mix of earnings there. So the – I would say the EBITDA impact to FX is more towards the top of that range, where the revenue impact I would say is more towards the low to the mid-point of that range. So figure somewhere between a half a basis point difference between revenue and EBITDA there. Other items, I did mention in my comments that we do have remediation efforts continuing in Brussels here into our fiscal 2023 that obviously is reflected into our guidance for sure. From a COVID standpoint, we mentioned in our prepared remarks that we have taking a two-thirds haircut to the volumes we saw in fiscal 2022, in our fiscal 2023 guidance that’s further de-risking from what was assumed as part of our May comments on our third quarter call here. And just given that decrease in volume and the absorption impact related to running at high levels of utilization on COVID dedicated lines, there is a relatively impact – relative impact to our overall margin profile as of – as a result of that. Supply chain and inflationary pressures, I would say continue to be a challenge. And in some cases, even I would say more of a challenge now than they were in terms of how we’ve talked about this in the past, we’ve seen more supply chain impacts to our SOT Segment specifically more recently around our ability to get our hands on active ingredients and other key inputs related to consumer health volumes, so that will play a role into the a little bit of the margin story here. And then just from an inflationary standpoint, I mean, look, just given the environment we’re in, we’re looking at impact related to wages that are probably about 2 times what we would’ve seen in a normal year, and that doesn’t take into account what we’re seeing on just the material side of things as well, obviously, where we’re able to pass those off to customers, we’re doing that, we’re going after price, where we can as well to help offset some of these pressures. But giving all of these moving pieces here to be sitting in a position on a constant currency basis where we are seeing modest margin improvement is a pretty good position to be in and what I would consider the most challenging macroeconomic environment, I’ve seen in my career. Lastly, I would just say we continue to be on track from a long-term margin target year Tejas, although, we’re not going to see the margin expansion of a 100-plus basis points like we’ve seen over the last several years. We remain committed to our 28% EBITDA margin by – I’m sorry, by our 30% EBITDA margin by fiscal 2026.
Tom Castellano: So Luke, I would maybe just start here by saying, I don’t know that there’s a significant variation around COVID volume to the low end here, I would say, the levels that we’ve taken COVID volume down is reflective of contractual obligations that we have with key customers and decreasing at two-thirds from where we were in fiscal 2021, puts it down to a relatively much smaller, smaller level than it has been contributing in the past. I would say, that’s not an assumption that I would say is really the variability here in terms of the guidance range. Now there’s obviously if we see any significant increases here related to COVID demand that can factor into the high end or outside on the high end of the range. But I wouldn’t say that there’s material swing and the assumption around COVID throughout the range of guidance. I would say, the real variability here in terms of our range is just a lot of the supply chain related challenges that we saw. And are we going to have any difficulty in getting our hands on materials there. As I mentioned, the midpoint of the range assumes that the macroeconomic environment we’re in today remain steady, if that were to get worse, that would be more of a potential impactor to the – to getting us towards the lower end of that range versus any further movement on the COVID side, which as I said, we feel pretty good around and is a pretty much a firm outlook here based on contractual obligations.
Tom Castellano: Yes. And I would just add to that, Luke, as I highlighted earlier in my comments to Tejas, a lot of the supply chain challenges that we’ve been seeing more recently have been impacting our SOT business and particularly on the consumer health side. So not geared towards those large molecule biologic assets that you are referencing, yes.
Tom Castellano: Sure. So look, I would say, with the de-risking here from a guidance standpoint, you broke up a little bit during the second part of your question, Julia, so I’ll do my best here to answer it. But in terms of the first part, we did mention that we are seeing the base business here growing in excess of 25% in the fiscal year. That’s going to be a significant offset to the two-thirds reduction in COVID related volume that we have in our fiscal 2023 guidance. And that does contemplate growth across all of our technology offerings. I would say, from a biologic standpoint, we are seeing X growth – X COVID growth on the drug product side. But obviously, cell and gene therapy is a significant contributor to the fiscal 2023 growth story. That was a business that was not significantly impacted by COVID related demand, our drug substance business out of both Madison and Bloomington as well as capacity that we’ll be bringing online in Europe as a result of the Oxford facility. That was another business that is obviously not significantly impacted by COVID related demand that we will be seeing growth from in fiscal 2023. I think there may have been a part of your questions around COVID therapeutics in here. I would say, COVID therapeutics are not a significant growth driver as we’ve talked about. The bulk of our COVID related revenue has been from more vaccine related revenue. And in terms of – I think the second part of your question was related to supply chain challenges and what the impact there is. And I think we’ve talked about that already mostly impacting our – the consumer health side of the business in terms of inflationary pressures. We are seeing wages up two times to what they would be in a normal year, as well as seeing increases for many suppliers on the vendor side. And then we’re looking to be active in terms of being able to recoup that through our customers where our contracts give us the ability to, as well as, I would say, driving off cycle price increases where we’re able to from customers to ease that impact. But again, despite all of those challenges, we are looking at modest margin expansion at the midpoint of our fiscal 2023 guidance on a constant currency basis.
Tom Castellano: So I’ll start here. Alessandro feel free to jump in. So I’ll start with your last question first, Derik. Look, we’re not in a position at this point to give guidance around fiscal 2024. And I think there’s still a lot to understand in terms of what the macro environment looks like today and what that – where that heads over the next year. What I have said is we’re absolutely on track and continue to be confident about our ability to deliver on the 30% EBITDA margin target for fiscal 2026. In terms of the organic revenue growth on a segment by segment basis, I would say, that’s not something we’ve talked about here, specifically we did make comments in our prepared remarks that we’re seeing 25% business – a 25% growth across our business excluding COVID demand. I think you can do some math and come based on disclosures we’ve made here as well as based on customer concentration related disclosure, that will be in our 10-K and be able to estimate in a pretty tight demand what the COVID-related impact is here. And I would say, as you take that into consideration, it’s very difficult to have a two thirds related volume headwind on COVID and be able to see growth within biologics, including that in the 10% to 15% range. So, I think you can maybe take from that where we are there, and from a SOT, OSD basis, we’ll obviously be reporting those out as our Pharma and Consumer Health segment starting in next quarter. And that is a business that’s growing outside of here in 2023 guidance that 6% to 10% long-term outlook here, obviously considering we’re seeing 25% growth across the business on the next COVID basis.
Tom Castellano: Yes. Look Jack, we’re going to fall short of giving specific quarterly guidance here, but let me just give you some directional commentary. I would say as we did make a point here to reference seasonality that we see in this business. And I would say, what we’re seeing in fiscal 2022 probably feels a little bit more like what we’ve seen in fiscal 2020 and prior to that, given that fiscal – I’m sorry, I’m referring to fiscal 2023 now, feeling more like fiscal 2021 and fiscal 2020 from a seasonality perspective, more so than what we saw fiscal 2022, which was obviously a year that was significantly skewed by COVID-related increases through sequential quarters until we got to our fourth quarter where the volume declined here. We did mention about 60% of our absolute dollar EBITDA being generated in the second half of the fiscal year; bring 40% of that for the first half of the fiscal year. And I would say, in terms of the quarterly phasing, again, going back to what Q1, Q2 splits looked like in that in that 2019, 2021 time period is probably a close proxy to how you can see the year play out from a quarterly phasing standpoint in 2023.
Tom Castellano: So, we’ll get more specifics around the guidance here of metrics when we do close the transaction, which we’re hoping to do by the end of the calendar year here. We did talk about growth rates that we expect to see from that business being very closely aligned to that, of what the new Pharma and Consumer Health business of 6% to 10% would look like. And you can use that $90 million as a base, knowing that obviously this will only be a partial year contribution that we would see in fiscal 2023. And again, that exactly how much will depend on the timing of the close and the transaction. So, we’ll give some more specifics around the revenue and EBITDA contributions, the fiscal 2023, once that deal closes in the first call post close.
Tom Castellano: Yes, look, I think it's – I think you're right. We did mention both here. We mentioned that with the declining COVID-related revenue that we will see the component sourcing dynamics start to normalize here in the year. And then obviously in talking about some of the margin pressure opportunities here, we talked about the – we've talked about the absorption related items driven volumes. I would say, the point of referencing the component sourcing piece is really more material for the Biologics segment than I would say it is for the company overall. Meanwhile, the absorption piece does have a more meaningful impact on the company overall here that they've just given the fact that we're talking about dedicated capacity that was running at very high levels of utilization and being replaced, whether on the same asset or in other assets that we've brought online during that period here. I'm not quantifying each of those for you, but I would say they essentially offset each other. But there's probably a little bit more impact to the bottom line here from an absorption standpoint just as we start to ramp up other assets that we brought online during the COVID pandemic that are – I would say, slow on the uptake here, right? You don't plug in a new syringe line and be operating at 85%, 90% utilization and start to see that full absorption, right? There's a ramp up period here that we see that takes into consideration. But I would say, the fact that we're in, again, in a position where we are seeing modest margin expansion despite a lot of these moving pieces and challenging macroeconomic environment is something we're pleased with and we're obviously going to look to maximize the margin expansion opportunity that we have here in fiscal 2023 on our path towards the 30% by fiscal 2026.
Tom Castellano: Yes. And I'll just add Justin to that related to Oxford specifically. This was a pivot for us here in terms of building out capacity for European drug substance originally in our Anagni facility, and then we were able to accelerate that with the acquisition of Oxford. So our original drug substance plan didn't have revenue contribution until probably midway through our Fiscal 2024 year, if not later. And as Alessandro said, as a result of this acceleration through what we've – what we acquired as well as the capacity we're deploying in that site, we would be in a position to be able to see revenue contributions laid in Fiscal 2023.
Tom Castellano: Yes. And I would just add Sean; this gives us even more confidence than we already had around being able to achieve our fiscal 2026 long term EBITDA margin of, a target of 30%.
Tom Castellano: Yes, I think it's a great point, Evan. And I think we historically have been spending capital at the clip of somewhere between 8% to 10% we were at that time somewhere between a 4% and 6% grower, maybe 4% and 8% tops and with the capital that we've deployed over the last couple of years into biologics. I think it's been pointed out to me that many of our peers that are more heavily Biologics weighted than we are spending something like 20%, 25% of revenue. Look, I think Alessandro's points here around what we're seeing on the pharma and consumer health side of the business being less capital intensive, but yet seeing the growth is accurate. This year we've talked about spending something in that 13% to 15% of range. I don't think that a normal year for us is 8% to 10% any longer given the mix shift of assets we now have in the portfolio, it feels like the normal for us. Now, just given how much maintenance we have across 50 plus rooftops, feels more like about 10%. So we do need to get back down to that 10%. I don't know that we get there exactly next year, but we'll obviously get some more specifics around how this phase is out, but I would expect 13% to 15% this year, probably a step down from that level of next year. Probably not quite to the 10% normal run rate, but then thereafter getting close to, if not at that 10%. And that being the new sort of base CapEx level of deployment to expect.
Alessandro Maselli: Sure, sure. Look, this is very simple in many ways although not easy as it’s required a little bit of organizational adjustment. Look, when you look at the percentage of our customers, which are buying more than one service from Catalent, this is still a relatively low percentage. And when you look at where the customer base is going with the more and more customers, which are more on the small side, the biotech type of customers, clearly they have the need of way more than just one service out of Catalent. And there is an opportunity there to significant increase the share of existing customers, which and the new customers will enjoy more than one service out of a Catalent offering. In the past, our previous organization was creating some internal barriers from that web, both from a go-to-market strategy from an execution standpoint. And by combining all of these together, three those barriers have been removed. There are incentive plans allowing people to benefit from across cross offering wings. And we are already seeing since the onset of these new organizations, some very good trends in these regards. So with regards of the increased guidance for this segment, look, we have made the rights investments in the gummy business. We already said that this gummy business is growing significantly above the average of this segment. We also have expanding and resolved some bottleneck we have in the capacity on the complex or solid the business in North America, which were constraining in the past little bit growth was a self constrained. We did have demand, that we see demand. And we couldn’t really enjoy the whole demand that we were seeing there. And lastly, the fact that we are now both organically and inorganically opening up our offering to high potent, which is the fastest growing sub segment of oral solid, primarily driven by oncology pipeline. All of that combined really has an impact on the expected growth rate of these segments. So in many ways, these are – these were things in the making over the last two years unlocked by these new organization.
Alessandro Maselli: Yes. The other piece I would add Luke here is, during the spring, we have said many times that there was still a number of variables significant – significantly impacting the potential outlook on COVID vaccine demand. And those variables were primarily related, what is our second half for our fiscal year, meaning the first half of next calendar year. So some of those variables have settled now and our creator primarily with the regards of how the vaccine are going to behave from a seasonal standpoint. We made the reference in our script that now we have a pretty good outlook around the seasonality of the vaccines and so forth. And so we are in a better position to forecast the second half of the – our fiscal year, which is the first six months of next year. So I believe that this is a solid outlook we are providing today.
Alessandro Maselli: Look, when it comes to these new assets, these new assets, where is a combination of several assets which were meant to meet demand in a number of therapeutic areas, which we have seen over the last three years potentially in high demand. One of this is diabetes, which combines now with some obesity as well. Neurological disorders and surely oncology, the new approved cell therapies for the oncology pipeline are pretty remarkable. And this is an area where we see opportunities. So all these assets were primarily built to meet this demand coming from these indications and therapeutic areas.
Alessandro Maselli: Sure. Look. Clearly, we don’t give very short-term indications of guidance by single segment. But in terms of answering broadly to your question, we are already seeing the transition of that segment accelerating towards the new growth that we have projected as I said, that is driven. If you look at the factors that I did mention, which are behind that acceleration some of them were already in play in the last couple of years, right? So the addition of the gummy business will be completely organic this year. There is only one quarter where it’s going to be inorganic. So not only now we have a full ownership of the asset, but we are very much accelerating on expanding capacity to meet the high demand in that area. Our expansions and acceleration on complex are all solid North America as well has been quite executed well by the team and is coming available for executing on programs, which we have secured over the last few years. And I would say in general, there is a continued to rebound our consumer product with specifically cough and cold categories and so pain relief which is another area where we are seeing significant demand. If anything there we’re trying to overcome some supply challenges. So when you look at all of these dynamics, which I did mention these are dynamics that have been in play already in the last few quarters and coming to fruition. On top of that, we are confident that they accelerated commercial synergy. So we are going to enable with the new organization will allow to further accelerate these growth.
Alessandro Maselli: Yes, sure. Look, as you pointed out, it’s quite remarkable, the capacity that we have added and with the remaining execution that we’re going to do, what I can tell you is that by continuing on that execution and the plan we have in the last next 18 months – 18 to 24 months, we are very well positioned to deliver our fiscal 2026 target, if you like. So in many ways we have already created a significant amount of the capacity that once getting utilized that will deliver the fiscal 2026 target. So probably this is giving you a little bit of quantitative measure of the capacity being created. But another way to look at that, look, when it comes to drug product, we’ve been primarily focusing complementing the offering with the syringes on top of vials. And when it comes to drug substance we’ve been just doing expansion, identifying our production, production schedule. And when it comes to gene therapies, will be essentially going from a 10 suites to 18 suites in BWI. So this again gives you a little bit of a measure of what is the potential of this capacity going forward.
Alessandro Maselli: Look, the transition is mostly seamless, meaning that is happening in parallel. One thing that is happening is that mostly the lines in which we are transferring new products, we’ve been transferring and onboarding new programs are lines which were built in parallel of the COVID lines. We always wanted to have the possibility to serve new customers and new programs, while still leaving enough capacity to satisfy the COVID vaccine demand, which in many ways is still not totally predictable, although we’re now getting to a much better visibility on it. So I would tell you that the transition has been pretty seamless. You don’t have to think about these like stopping vaccine and starting something new, but is mostly things that are happening on different formats and on different production lines. With regards of some of the ones that are in fact going to be served out of the current COVID vaccine lines, which are going to – remember, on the entirety of the current of all vaccine supplies made in vials for some of these programs to a large extent we can onboard them and validate them on the line, while still making the vaccines. So it’s a kind of phase in phase out type of dynamic as opposed to having a gap in between.
Alessandro Maselli: Yes. So, look with regards of your question around the take of pace has been kind of a routine question over the last few months. Again, year-do-date what I’ve already shared while we feel strong about our take of pay commitment and so on. We’d also very mindful of being partners with our great clients and making sure that we listen them to the needs. And we try to find a win-win solution for a landscape that is very hard to read for everyone. So, in many ways, the breadth of the offering of Catalent gives us optionality in sometimes to trade some of the – what is due volumes in these contracts with something else. I believe that part of the success we are having in non-COVID business, which is growing at more than 25% is also due to this approach, which have been very, very successful in securing long-term, good outlook on non-COVID or non-COVID business as leveraging those relationship and our partnership approach. So, we feel good about our approach so far. We believe that’s created a momentum in non-COVID business and is part of our – is partly behind our confidence in the long-term prospects of the company.
Alessandro Maselli: I would just add one comment more general. One reason why we do like the space. So prescription on a solid is that you normally have a pretty good visibility on the revenue. So for a fairly good horizon, given the prescription nature of the business and the strength of the pipeline. 
Alessandro Maselli: That’s a great question. I believe, we are in a pretty good place. I look, we’ve been always very happy about our sales machine, which has been producing consistent organic growth over the last four, five years I would say. Here is more in terms of making sure that when one of our sales rep engages with the customer, and we do have relations with the customer, we take the full advantage of the relationship and try to offer more than just one service. So, I would say that look, the, I cannot point to a specific percentage of completion of the plan, but we are pretty advanced in what we are trying to implement here. Our basics and foundations, so our sales machine remain very, very strong and what they drove, really success in the last few years and is, this is the way you need to see is not a revolution, but an enhancement of the good market strategy so that we can unlock value where the value was blocked by our internal barriers.
Alessandro Maselli: Yes. Yes, sure. Look, I believe that on the Biologics side that we’re allowed to remain pretty much the same that was before, that's really not what is driving at this increase. We remain very bullish on the Biologics story at 10% to 15%. What is driving the overall increase in the growth expectation from the company is if you like the assets, which were a little bit behind in the growth story of the company, dragging down the overall growth rate perspective for the company, which were more in the small molecule side and very fashioning of the small molecule footprint, we were able to implement through the pandemic, which went a little bit under the radar. I understand that during the pandemic, everything that was making the news was related to biologics, vaccines and so on. But we were working very, very hard in the background in addressing some of the gaps we had in the small molecule portfolio to enable faster growth there. And I will point out again, primarily in the consumer health, getting on top of these very high demand the dosage form of gummies and soft chews, which is again, is a significant contributor to that acceleration the fact that we've been investing organic and in our Kentucky facility, in our Florida facility, which are serving the complex, oral solid market in the United States, which is very, very healthy at this point in time, as well as leveraging some of the dynamics in the consumer health after an initial period of if you like a crisis at the beginning of the pandemic came back pretty, pretty strong. So it's more on the PCH side that you need to see the increase, we have increased 200 basis points of the top end on the PCH side compared to the past. And this is really what is driving our most, more comfortable outlook about the company and really putting us in a comfortable position to raise our long-term guidance for the organization.
Alessandro Maselli: David, we hadn't disclosed exactly what the contribution was there. We did point to the fact that it was a significant driver of margin profile. So I think if you were able to do that math and triangulate something in that range, I think that's directional.
Alessandro Maselli: And as a follow-up comment on these I would tell you clearly as the vaccines for COVID the transition from pandemic to endemic use, they will resemble a little bit more the fact that no other vaccines, which means that you're going to produce a significant amount of volumes in a shorter timeframe and the rest of the area you're essentially in a much lower production mode. So that is a little bit more challenging to manage from an absorption and profitability standpoint is something that takes some time to organize yourselves for. And that's why I believe we have a very good plan. We are discussing this also with our partners, but is a dynamic that needs to be taken into account as you move from the pandemic where you essentially running flat out through the 12 months. You move into a more traditional vaccine manufacturing, which has that challenge always had – it will always have.
Alessandro Maselli: So look, clearly, we see these – with these fiscal 2023, a little bit as a transition year from a strategic standpoint is notable the fact that we are reducing two thirds our expectation from COVID vaccines. And at the same time, we are in line with expectations. And that will point you towards, the – what we shared around the non-COVID business and the strength there, right? So we have highlighted that is above 25%. I believe you guys can, can make some math and be a little bit more accurate on that. We provided all the relevant information to be, to do so. But that that is telling us that all the moves we've done refreshing, retooling our portfolio on the remaining business, put us in a very strong position as we transition outside the pandemic.
Alessandro Maselli: Well, look from our perspective we've been pretty pleased with the approvals that have been impacting our pipeline and we see further opportunities going forward. So look, it's a little bit not necessarily the macrodynamic of the approvals that happens out there significantly impacts Catalent. It depends – it's very discreet, right, and very, very much focused on some products. But I am going to tell you, we've been seeing some good success of the products in our pipeline in the last few quarters.
Alessandro Maselli: Sure. So very different answers for those facilities. So with regards to Princeton, commercial cell therapy capacity is mostly already online. Any fact that is already one product, which is late stage running there. We've seen very, very strong interests out of the gate after we announced it. And it's more related to the time for us to onboard these programs than the capacity. So the constraining factor in Princeton is really around our ability to close these deals and onboard these tech transfers and these activities into facility, which again, I remember everybody is skewed more toward the late stage. So we are talking about mature cell therapy programs, which are trying to find home for the commercial Phase 3/commercial needs, so that's Princeton, cell therapy serving mostly oncology therapies. With regards of Oxford, there is a little bit of a different story. The build out is proceeding at pace. I believe that we are very closer to open our PD side of the house where we're going to start working on if you like of the scale-up of these cell lines. So this facility will be mostly serving messenger RNA and proteins to a large extent. And then the larger scale bioreactor will come a little bit later in the year. We expect that these assets to start generating revenues as we said in the last past of the fiscal year. We believe that Princeton is going to be a little bit fasting index.
Alessandro Maselli: So look I believe that the first – before the summer we didn't see significant moves in the evaluations and so forth. As if the space was still waiting to factoring the new reality of multiples into the assets. I believe we are still – we are starting to see some early signs of a more, catching up with the, the current environment, especially when it comes to cost of capital and macro economical uncertainty of the next couple of years, as well as private funding. So I believe that as we move in the next few quarters, I do expect some correction there. I will add though that the premium assets in our space are still kind of expensive because they have a pretty good strategic prospecting front of them. So I believe it's a little bit of a mixed back. I would tell you that of course multiple can constitute an odd dollar, but for Catalent is probably never only an evaluation of multiple and primarily our financial evaluation, more of a strategic evaluation? And how we're going to make sure that when we add an asset to Catalent, we can also accelerate growth and generate synergies out of these, and not only enable more growth out of Catalent, while we can also accelerate growth into these. This is what we believe formatics. We believe that by inserting, there is a premium asset in our much larger commercial engine we'll accelerate pipeline, creation and tech transfers. On the other end, we expect that this offering – completing this offering in downstream high-potent capacity will create additional opportunities for some of our assets, which are more early stage, which didn't have necessarily a downstream capacity prior. So matrix is a squarely in the definition of that in terms of M&A. Catalent is always having a pretty healthy portfolio of M&A opportunities as we explore the market. And whenever we see an opportunity to accelerate growth and expand margin through what I just described, we definitely are interested in exploring the debt opportunity.
Alessandro Maselli: Sure. Look as I said on the commercial side, most of the foundations were already there. We needed to tweak a little bit, our incentive plans and so forth to make sure that we drive the right behaviors and remove some artificial P&L internal barriers, which were not really, enhancing our opportunities to sell across a portfolio offerings to our customers, which by the way, we'll buy them anyway, either from us or from others so better, they buy all of them from us. So on that side, I don't believe that there will be, any cost impact on the commercial side of the house. We did point towards that this organization is a little bit linear in terms of management and surely enables us to drive operational excellence across the board more effectively that we used to do before, sharing some best practices and surely, avoiding some duplication where you think about, for instance managing a program, which is both giving the customer formulation development, clinical material and at the same time distributing the clinical trials for their own trials. Clearly there is some synergy there in the way you manage this project close while before you had to manage different PCC slides. When in fact you had the different slides, which as I said, was not as common as could have been. So clearly in that regards, we see an opportunity here to continue to drive operational excellence and efficiency and linear approach. So bottom line is that yes, we do expect that these, this not only to drive accelerated top line growth, but also provide us a little bit of productivity and efficiency. 
Alessandro Maselli: So I will let Tom to provide some more color around how you should think about it. What I can tell you is that the fact that now this overall organic growth expectation is accelerated by the PCA segment as opposed to the Biologics segment, its good news in that regards because our PCA segment is significantly lower in terms of capital intensity towards Biologics. And again, that was very, very intentional from us. We recognize that our Biologics segment is very capital intense specifically when it comes to assets like protein, drug product, gene therapies and so forth. But when you look at complex oral solid, when you look at gummies, when you look at softgels, when you look at, early stage formulation development assets and so forth, these are assets we come without a lower capital intensity as a percentage of revenues. So as we accelerated that growth and that part continues to have a significant share of the portfolio of Catalent, overall this is good news in terms of capital intensity of the organization with the specific of biologics, I will let Tom to respond.
Alessandro Maselli: Thank you everyone for taking the time to join our call and your continued support of Catalent. We were pleased to deliver record result in fiscal 2022, and we are fully committed to deliver another strong year in fiscal 2023 and beyond. Thank you.
